What are the differences between developing products using traditional licensure pathways and the Animal Rule?
The major difference is that the Animal Rule allows efficacy to be demonstrated in animals rather than people. All other requirements for traditional licensure still apply. Phase 1, 2 and 3 clinical studies are still required to demonstrate safety and immunogenicity and to establish a link between the pivotal animal and human studies to predict clinical benefit.
